◇ Compound Reference
Amylin Analog · 10mg
Long-acting amylin analog on a pathway separate from GLP-1. Used as an optional GLP-1 stack (the CagriSema rationale) or as an alternate-pathway bridge during a physician-managed GLP-1 break.
Amylin Analog · 10mg per vial · dispensed after a physician review.
Cagrilintide is a long-acting amylin analog. It works through the amylin and calcitonin receptor system - a pathway entirely separate from GLP-1 - to regulate appetite and gastric emptying.
This mechanistic independence is what makes it useful both alongside a GLP-1 agonist and as an alternate-pathway option.
Non-selective agonist at amylin receptors (AMY1-3R) and the calcitonin receptor, concentrated in the area postrema and nucleus tractus solitarius of the brainstem. Generates satiety signals, slows gastric emptying, and suppresses post-meal glucagon.
Because it does not act on GLP-1 receptors, its effect is additive to incretin agonists rather than overlapping.
GLP-1 class - Tirzepatide, Retatrutide, Semaglutide, Cagrilintide, V-03, V-M2
These protocols work on appetite, insulin sensitivity, and how your body stores fat. Monitoring tracks both the metabolic benefit and the things that change quickly during weight loss - blood sugar, lipids, and lean-mass markers.
Incremental approach. Doses are titrated upward slowly from a low starting point. Maintenance is typically a moderate dose - pushing higher rarely adds benefit and adds side effects. Monitoring guides where you settle.
Educational only - not medical advice or a dosing instruction. Your physician orders the tests, sets your dose, interprets results, and decides if a protocol is right for you. See the Informed Consent & Disclaimer for full terms.
| Class | Long-acting amylin analogue |
| Mechanism | Amylin-receptor signalling; satiety and gastric-emptying modulation |
| Terminal half-life | Long-acting - once-weekly dosing studied in trials |
| Metabolism | Peptide degradation |
| Evidence base | Investigational - clinical trial stage, often studied with semaglutide |
| Regulatory status | Investigational; physician-supervised allocation only |
Phase 3a, 68-week RCT (n=3,417, without type 2 diabetes; NCT05567796) of the fixed-dose combination CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) versus each agent alone and placebo. Mean weight change was −20.4% with the combination versus −11.5% cagrilintide alone, −14.9% semaglutide alone, and −3.0% placebo (−22.7% under full adherence). This is the primary evidence for the STACK rationale - co-administering cagrilintide with a GLP-1, where two independent satiety pathways (amylin and incretin) act together. IMPORTANT SCOPE: this trial tests continuous co-administration. It does NOT evaluate using cagrilintide during a break from a GLP-1, and provides no evidence for "receptor resensitizing" - that bridge use is a separate, mechanistically-plausible-but-unproven hypothesis and should not be inferred from this result.
View on publisher ↗Two physician-supervised use patterns, tiered by evidence: (1) STACK - co-administering cagrilintide with a GLP-1 agonist mirrors CagriSema. This has the strongest support: REDEFINE 1 showed the combination (−20.4%) substantially exceeded either drug alone, consistent with two independent satiety pathways firing together and allowing lower doses of each to reduce GI side effects.
(2) BRIDGE during a GLP-1 break - using cagrilintide's separate amylin pathway to maintain appetite control while a patient is off their GLP-1. This is mechanistically plausible (cagrilintide does not rely on GLP-1 receptors) but is NOT supported by combination/sequencing outcome trials; the popular "receptor resensitizing" framing is largely unproven - plateaus are more often metabolic adaptation than receptor downregulation.
Vivre offers the bridge only as a physician-managed option with that uncertainty stated, never as an established protocol or a self-directed cycle.
Cagrilintide is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.
Are you 18 years of age or older?